News | Heart Failure | July 13, 2017

Vest Wearable Monitor May Reduce Heart Failure Readmissions

The SensiVest uses radar technology to detect the exact amount of fluid in the lungs

monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

A heart failure patient wearing the SensiVest remote monitoring system for a two-minute a day assessment. 

William Abraham monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

William Abraham, M.D., monitoring a heart failure patient's chest fluid buildup using the SensiVest remote monitoring system. The daily data points can show if a patient is starting to retain fluids prior to the onset of symptoms.

July 13, 2017 — About 5.7 million adults in the U.S. suffer from heart failure, and because of a dangerous buildup of fluid in their lungs, more than half of those patients end up back in the hospital within six months. But researchers say a high-tech vest that is entering U.S. trials may help doctors monitor a heart patient’s symptoms remotely, which may prevent the need for rehospitalization.

The SMILE Trial (Sensible Medical Innovations Lung fLuid status monitor allows rEducing readmission rate of heart failure patients study) will look at the efficacy of the SensiVest, a product developed by Sensible Medical Innovations, headquartered in Israel. The system is comprised of a wearable vest containing two embedded sensors, one in front and one behind the patient, and a bedside console. 

“The major cause of readmission for heart failure patients is excess fluid in the lungs,” said William Abraham, M.D., FACC, director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, who is leading a randomized, clinical trial of the vest. “The vest allows us to see when the lungs are trending toward being too wet so a patient’s medication can be adjusted before they even notice any symptoms.”

Watch a VIDEO showing how the vest works and to hear more about it from Abraham.

The vest uses radar technology to “see through” the chest and accurately detect the amount of fluid in the lungs. A patient wears the vest for just 90 seconds a day and the information collected is automatically uploaded to a cloud server. The patient’s cardiologist can review the data to determine if any treatment adjustments need to be made to restore the lungs to healthy fluid levels.

“This technology gives us absolute and actionable data of lung fluid content that we can use to keep patients healthy and out of the hospital,” Abraham said. “The fact that it is completely non-invasive and takes less than two minutes a day to use, allows patients to live a better quality of life with heart failure.”

A study initially conducted in Israel reported that hospital readmission rates were reduced by 87 percent for patients who were part of the study. 

The vest uses the same technology used by the military for things like “seeing through” walls before entering a building or searching through rubble for survivors after a natural disaster.

Watch a VIDEO discussion with Abraham on several new technologies to treat HF and reduce heart failure readmissions from TCT 2016.

Read the article "Reducing Heart Failure Readmissions."

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init